Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 6NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Osteoporosis 2Breast Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Radiotherapy 138Cyclophosphamide 108Cisplatin 103Doxorubicin 99Vincristine 76Filgrastim 60Etoposide 58Paclitaxel 56Carboplatin 53Fluorouracil 51Methotrexate 49Dexamethasone 49Cytarabine 43Prednisone 42Leucovorin 40Granulocyte Colony-Stimulating Factor 34Docetaxel 34Radiation 31Specimen Handling 30Tamoxifen 27Daunorubicin 27Magnetic Resonance Spectroscopy 26Calcium Dobesilate 26Ifosfamide 25Mercaptopurine 24Gemcitabine 24Platinum 22Goserelin 221,2-diaminocyclohexaneplatinum II citrate 22Chemotherapy, Adjuvant 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × NETWORK × Risedronic Acid × Clear all
NCT00354302 2020-04-02

Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial

Canadian Cancer Trials Group

Phase 3 Completed
497 enrolled
Breast

Breast Neoplasms, Osteoporosis

NCT00324714 2012-11-29

Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS

ETOP IBCSG Partners Foundation

Phase 3 Withdrawn
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Osteoporosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡